Theriva Biologics, Inc. (TOVX) Stock Analysis

Company Overview

Theriva Biologics, Inc. operates as a clinical-stage enterprise focused on developing therapeutics designed to address cancer and related diseases within areas of high unmet need in the United States. The company functions within the healthcare sector, specifically the biotechnology industry, where its primary objective is to advance oncology treatments through innovative product candidates. Its current scale is defined by a market capitalization of $9.28M and an employee base of 15, while annual revenue figures are not disclosed in the available financial data. The combination of a sub-$10M market cap and the absence of reported revenue indicates that the company remains in an early developmental phase where capital allocation is directed toward research and clinical trials rather than commercialization or profitability.

Financial Health

The company reports a net income of $-25,249,000 over the trailing twelve months, accompanied by an EBITDA of $-14,912,000, while revenue for the same period is not available. The significant negative net income relative to the reported EBITDA suggests a substantial cost structure associated with clinical trial expenses and operational overhead that directly impacts the bottom line before interest and taxes. Free cash flow stands at $-5,976,500, indicating that the company is currently consuming cash to fund its development activities rather than generating surplus liquidity from operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the typical financial profile of a clinical-stage biotechnology firm that has not yet achieved commercial sales to generate revenue-based profitability. The balance sheet shows a cash position of $13.06M against total debt of $2.63M, resulting in a debt-to-equity ratio of 17.09. Despite the nominal debt figure, the high debt-to-equity ratio mathematically suggests a leveraged capital structure when viewed against equity, though the absolute debt level remains low relative to cash reserves. Liquidity is supported by a current ratio of 1.74, indicating that the company holds sufficient current assets to cover its short-term obligations without immediate distress. Return on equity is -137.8% and return on assets is -25.5%, metrics that reveal the company is currently diluting shareholder value and utilizing assets to generate losses rather than returns as it pursues its clinical pipeline.

Valuation Assessment

The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is calculated at -1.01. The disparity between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing the stock based on future expectations of potential earnings rather than current historical performance. The price-to-book ratio is 0.47, suggesting that the company's market value is significantly below its book value, a common characteristic for pre-revenue biotechnology assets where intangible pipeline value is not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of 0.08, figures that suggest the company is trading at a valuation multiple that does not reflect traditional earnings-based pricing models. The stock has traded between a 52-week low of $0.16 and a 52-week high of $1.50. Based on the provided data points, the current trading position relative to this specific historical range cannot be quantified as a percentage without a real-time price input, but the range itself demonstrates a wide volatility corridor typical for small-cap clinical entities. The beta value is 0.52, indicating that the stock's price volatility is less than the broader market, moving at a lower rate of fluctuation compared to the overall index.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning specific growth rates cannot be calculated from the current financial statements. The absence of revenue data prevents a direct comparison between the pace of earnings growth and revenue growth, as both are currently undefined in the public record. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available earnings and capital are retained and reinvested into research and development rather than distributed to shareholders. This reinvestment strategy is standard for clinical-stage companies that prioritize pipeline advancement over income generation for investors. The overall growth and income profile is characterized by zero current profitability, zero dividend yield, and undefined growth rates, reflecting a business model entirely dependent on future clinical success and external capital raising to sustain operations.